CA Patent

CA3202575A1 — Treatment of raynaud's disease

Assigned to Aisa Pharma Inc · Expires 2022-06-02 · 4y expired

What this patent protects

Disclosed herein are methods of treating Raynaud's syndrome (e.g., secondary Raynaud's syndrome) in a subject in need thereof, using a dual N-type and L-type calcium channel blocker selective for the N-type calcium channel and/or a phosphodiesterase type 5 inhibitor.

USPTO Abstract

Disclosed herein are methods of treating Raynaud's syndrome (e.g., secondary Raynaud's syndrome) in a subject in need thereof, using a dual N-type and L-type calcium channel blocker selective for the N-type calcium channel and/or a phosphodiesterase type 5 inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number: CA3202575A1
Jurisdiction: CA
Classification: —
Expires: 2022-06-02
Drug substance claim: No
Drug product claim: No
Assignee: Aisa Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.